Orexo AB ORX -Financial Strategic SWOT: Ken Research
Orexo AB (ORX)-Financial and Strategic SWOT Analysis Review

Orexo AB (ORX)-Financial and Strategic SWOT Analysis Review

  • Products Id :- GDPH82277FSA
  • |
  • Pages: 54
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Orexo AB (ORX)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company operations and business divisions.

Corporate strategy-Analyst summarization of the company business strategy.

SWOT Analysis-A detailed analysis of the company strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.


Orexo AB (Orexo) is a specialty pharmaceutical company that focuses on the research, formulation, development, registration and commercialization of drugs. The company commercial product portfolio consists of Abstral, Edluar and Zubsolv. its pipeline candidates comprise OX51 for procedure-induced pain; OX-CLI for respiratory tract diseases; and OX-MPI for inflammation. The company uses its proprietary drug delivery technologies in the development of these products. It also carries out the industrial-scale production of pharmaceutical products. Orexo has strategic collaborations with various pharmaceutical companies such as Meda, Kyowa Hakko Kirin, Sentynl Therapeutics, ProStrakan, AstraZeneca and Mundipharma for the development and commercialization of its product portfolio. Orexo is headquartered in Uppsala, Sweden.

Orexo AB Key Recent Developments

Jul 11,2017: Orexo Interim Report Q2 2017

Apr 20,2017: Orexo: Interim Report Q1 2017

Jan 26,2017: Orexo: Full Year Report 2016

Oct 20,2016: Orexo: Interim Report January-September 2016

Jul 12,2016: Orexo: Interim Report January-June 2016

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Section 1-About the Company 5

Orexo AB-Key Facts 5

Orexo AB-Key Employees 6

Orexo AB-Key Employee Biographies 7

Orexo AB-Major Products and Services 8

Orexo AB-History 9

Orexo AB-Company Statement 13

Orexo AB-Locations And Subsidiaries 14

Head Office 14

Other Locations & Subsidiaries 14

Joint Venture 15

Section 2-Company Analysis 16

Orexo AB-Business Description 16

Orexo AB-SWOT Analysis 17

SWOT Analysis-Overview 17

Orexo AB-Strengths 17

Orexo AB-Weaknesses 18

Orexo AB-Opportunities 19

Orexo AB-Threats 20

Orexo AB-Key Competitors 21

Section 3-Company Financial Ratios 22

Financial Ratios-Capital Market Ratios 22

Financial Ratios-Annual Ratios 23

Performance Chart 25

Financial Performance 25

Financial Ratios-Interim Ratios 26

Financial Ratios-Ratio Charts 27

Section 4-Company's Lifesciences Financial Deals and Alliances 28

Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 28

Orexo AB, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 29

Orexo AB, Recent Deals Summary 30

Section 5-Company's Recent Developments 31

Jul 11, 2017: Orexo Interim Report Q2 2017 31

Apr 20, 2017: Orexo: Interim Report Q1 2017 38

Jan 26, 2017: Orexo: Full Year Report 2016 39

Oct 20, 2016: Orexo: Interim Report January-September 2016 40

Jul 12, 2016: Orexo: Interim Report January-June 2016 42

Apr 21, 2016: Orexo: Interim Report January-March 2016 43

Jan 28, 2016: Full year report January-December 2015: Orexo 44

Section 6-Appendix 50

Methodology 50

Ratio Definitions 50

About GlobalData 54

Contact Us 54

Disclaimer 54

List of Figures

Orexo AB, Performance Chart (2012-2016) 25

Orexo AB, Ratio Charts 27

Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 28

Orexo AB, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 29

List of Tables

Orexo AB, Key Facts 5

Orexo AB, Key Employees 6

Orexo AB, Key Employee Biographies 7

Orexo AB, Major Products and Services 8

Orexo AB, History 9

Orexo AB, Subsidiaries 14

Orexo AB, Joint Venture 15

Orexo AB, Key Competitors 21

Orexo AB, Ratios based on current share price 22

Orexo AB, Annual Ratios 23

Orexo AB, Annual Ratios (Cont...1) 24

Orexo AB, Interim Ratios 26

Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 28

Orexo AB, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 29

Orexo AB, Recent Deals Summary 30

Currency Codes 50

Capital Market Ratios 50

Equity Ratios 51

Profitability Ratios 51

Cost Ratios 52

Liquidity Ratios 52

Leverage Ratios 53

Efficiency Ratios 53

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

select a license

Single User License
USD 125 INR 8431
Site License
USD 250 INR 16863
Corporate User License
USD 375 INR 25294



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com